The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 28, 2024
Filed:
May. 05, 2023
Applicant:
Generate Biomedicines, Inc., Somerville, MA (US);
Inventors:
Francesco Borriello, Cambridge, MA (US);
Alexis Hiram Ramos, Wilbraham, MA (US);
Assignee:
Generate Biomedicines, Inc., Somerville, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/10 (2006.01); A61K 31/13 (2006.01); A61K 31/215 (2006.01); A61K 31/45 (2006.01); A61K 31/4706 (2006.01); A61K 31/4965 (2006.01); A61K 31/675 (2006.01); A61K 31/7052 (2006.01); A61K 31/7068 (2006.01); A61K 31/7088 (2006.01); A61K 39/215 (2006.01); A61K 39/42 (2006.01); A61K 45/06 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/1003 (2023.08); A61K 31/13 (2013.01); A61K 31/215 (2013.01); A61K 31/45 (2013.01); A61K 31/4706 (2013.01); A61K 31/4965 (2013.01); A61K 31/675 (2013.01); A61K 31/7052 (2013.01); A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 39/215 (2013.01); A61K 39/42 (2013.01); A61K 45/06 (2013.01); A61P 31/14 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/55 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01); C07K 2319/00 (2013.01);
Abstract
The disclosure provides, in various embodiments, polypeptides (e.g., antibodies and antigen binding fragments thereof) that specifically bind to S2 domains of betacoronavirus Spike glycoproteins, such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike glycoproteins. The disclosure also provides, in various embodiments, fusion proteins comprising one or more of polypeptides, polynucleotides encoding polypeptides, vectors and host cells suitable for expressing polypeptides, and methods for treating viral infections (e.g., COVID-19).